Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Nasdaq  >  Vertex Pharmaceuticals    VRTX

VERTEX PHARMACEUTICALS

(VRTX)
  Report
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq
02/22/2021 02/23/2021 02/24/2021 02/25/2021 02/26/2021 Date
214.96(c) 216.44(c) 217.04(c) 212.98(c) 210.89 Last
3 671 871 2 600 916 1 775 785 1 830 557 1 587 872 Volume
+3.84% +0.69% +0.28% -1.87% -0.98% Change
More quotes
Financials (USD)
Sales 2021 6 947 M - -
Net income 2021 2 558 M - -
Net cash position 2021 9 146 M - -
P/E ratio 2021 21,6x
Yield 2021 -
Sales 2022 7 674 M - -
Net income 2022 2 994 M - -
Net cash position 2022 13 106 M - -
P/E ratio 2022 19,0x
Yield 2022 -
Capitalization 55 366 M 55 366 M -
EV / Sales 2021 6,65x
EV / Sales 2022 5,51x
Nbr of Employees 3 400
Free-Float 99,8%
More Financials
Company
Vertex Pharmaceuticals Incorporated specializes in the research, development and marketing of micromolecular drugs primarily for the treatment of cancers, viral, inflammatory and auto-immune diseases. Net sales break down by type of income as follows: - income from sales of products (99.9%); - royalties and income from partnership, research, and development agreements (0.1%). Net sales break down geographically... 
More about the company
Notations Surperformance© of Vertex Pharmaceuticals
Trading Rating : Investor Rating :
More Ratings
All news about VERTEX PHARMACEUTICALS
02/25VERTEX PHARMACEUTICALS : to Present at the Cowen Health Care Conference on March..
AQ
02/24VERTEX PHARMACEUTICALS :  Vertex to Present at the Cowen Health Care Conference ..
BU
02/23VERTEX PHARMACEUTICALS : Baird Upgrades Vertex Pharmaceuticals to Outperform Fro..
MT
02/22VERTEX PHARMACEUTICALS : Significant Insider Sales in Shares of Vertex Pharmaceu..
MT
02/19INSIDER TRENDS : Insider at Vertex Pharmaceuticals Disposes of Shares for Tax Sl..
MT
02/19INSIDER TRENDS : Insider at Vertex Pharmaceuticals Sells Stock for Taxes Interru..
MT
02/17VERTEX PHARMACEUTICALS : VRTX) Insiders Make Significant Share Sales Extending t..
MT
02/16FREELINE THERAPEUTICS : Names Michael Parini COO; CFO Resigns
MT
02/14INSIDER TRENDS : Vertex Pharmaceuticals Insider Makes Tax Sale Interrupting 90-D..
MT
02/14INSIDER TRENDS : Vertex Pharmaceuticals Insider Disposes of Shares for Tax Slowi..
MT
02/14INSIDER TRENDS : Vertex Pharmaceuticals Insider Sells Shares for Tax Slowing 90-..
MT
02/14INSIDER TRENDS : Vertex Pharmaceuticals Insider Sells Stock for Taxes Interrupti..
MT
02/14INSIDER TRENDS : Vertex Pharmaceuticals Insider Makes Shares Sale for Tax Slowin..
MT
02/14INSIDER TRENDS : Insider at Vertex Pharmaceuticals Sells Shares for Tax Slowing ..
MT
02/14INSIDER TRENDS : Insider at Vertex Pharmaceuticals Makes Tax Sale Interrupting 9..
MT
More news
News in other languages on VERTEX PHARMACEUTICALS
02/01Choc(s) de réalité sur les marchés
02/01EN DIRECT DES MARCHES : Danone, Bouygues, Valneva, Albioma, Nintendo, Julius Bär..
01/29VERTEX PHARMACEUTICALS : meldet Annahme des IND-Antrags für VX-880, eine neuarti..
01/29VERTEX PHARMACEUTICALS : annonce que la FDA a approuvé sa demande IND de « nouve..
2020VERTEX PHARMACEUTICALS : Veröffentlichung des Quartalsergebnisses
More news
Analyst Recommendations on VERTEX PHARMACEUTICALS
More recommendations
Chart VERTEX PHARMACEUTICALS
Duration : Period :
Vertex Pharmaceuticals Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends VERTEX PHARMACEUTICALS
Short TermMid-TermLong Term
TrendsBearishBearishNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 30
Average target price 283,73 $
Last Close Price 212,98 $
Spread / Highest target 62,9%
Spread / Average Target 33,2%
Spread / Lowest Target 17,4%
EPS Revisions
Managers and Directors
NameTitle
Reshma Kewalramani President, Chief Executive Officer & Director
Charles F. Wagner Chief Financial Officer & Executive Vice President
Jeffrey M. Leiden Executive Chairman
David Matthew Altshuler Chief Scientific Officer & EVP-Global Research
Carmen Bozic Chief Medical Officer & EVP-Medical Affairs
Sector and Competitors
1st jan.Capitalization (M$)
VERTEX PHARMACEUTICALS-9.88%55 366
GILEAD SCIENCES, INC.9.35%78 709
WUXI APPTEC CO., LTD.9.26%55 560
REGENERON PHARMACEUTICALS-5.07%47 197
BEIGENE, LTD.27.61%30 160
BIONTECH SE37.79%27 047